Auris Medical - Model AM-101 - Keyzilen for Acute Inner Ear Tinnitus - Datasheet

Auris Medical is developing Keyzilen for the treatment of acute inner ear (peripheral) tinnitus following traumatic cochlear injury or otitis media (middle ear infection). Keyzilen contains Esketamine hydrochloride, an N-Methyl-D-Aspartate (NMDA) receptor antagonist, formulated in a biocompatible and fully biodegradable gel. It is administered in one treatment cycle, comprising three intratympanic injections over 3 to 5 days into the middle ear. From there the drug diffuses through the so-called round window membrane into the cochlea.